Search Results - "melanoma"
Suggested Topics within your search.
Suggested Topics within your search.
- Neoplasms
- Cancer 3
- Immunotherapy 3
- Melanoma 3
- therapy 3
- immunology 2
- methods 2
- therapeutic use 2
- Adjuvants, Immunologic 1
- Adoptive Transfer 1
- Antibodies, Monoclonal 1
- Antigens, Viral 1
- Antineoplastic Agents 1
- Breast 1
- Breast Neoplasms 1
- CD8-Positive T-Lymphocytes 1
- Cancer Vaccines 1
- Cancer vaccines 1
- Colon (Anatomy) 1
- Colonic Neoplasms 1
- Drug targeting 1
- Gastrointestinal Neoplasms 1
- Granulocyte-Macrophage Colony-Stimulating Factor 1
- Herpesvirus 1, Human 1
- Immunological aspects 1
- Immunotherapy, Adoptive 1
- Indicators and Reagents 1
- Oncolytic Virotherapy 1
- Pathology 1
- Simplexvirus 1
-
1
Cancer pathology
Published 2020Table of Contents: “…Contents: Cancer pathology -- Histology -- Melanoma -- GI colon cancer -- Breast cancer.…”
Get full text
Series
Electronic Video -
2
Cancer vaccines part 1 of 2 /
Published 2015Table of Contents: “…Contents: The hallmarks of cancer -- Categories of cancer-associated antigens -- Viral & non-viral cancers: vaccine targets -- Immunotherapeutics -- Immunologic reagents approved for cancer therapy -- Clinical outcome based on immune response -- CTL-based therapy -- Virus-specific CTL adoptive transfer therapy -- Immunotherapy for Melanoma.…”
Get full text
Series (Immunotherapy of cancer)
Series (Vaccines)
Electronic Video -
3
Talimogene laherparepvec first-in-class oncolytic immunotherapy /
Published 2016Table of Contents: “…Contents: Causing tumour cell lysis -- Initiating a specific systemic immune response -- T-VEC as an oncolytic HSV-1 strain -- Assessing cancer immunotherapy through melanoma -- Applicability of oncolytic viral therapy to various cancers.…”
Get full text
Series
Electronic Video -
4
Checkpoint blockade in cancer immunotherapy
Published 2007Table of Contents: “…Contents: Activation of naive T-cells -- CD28 and CTLA-4 -- Differential regulation of T-cell responses -- Responding repertoire -- Biological role of CTLA-4 -- Tumor-specific immune responses -- Treg activity -- CTLA-4/GVax -- Immunotherapies -- Conventional therapies -- Ipilumumab -- Clinical studies: melanoma -- Reversible immune mediated toxicity.…”
Get full text
Series
Electronic Video